Search Results

AZD4017 5mg 5mg  | Purity Not Available

Adooq Bioscience

AZD4017 is a potent, selective, and orally bioavailable11b-HSD1 inhibitor (11b-hydroxysteroid dehydrogenase type 1 inhibitor).

More Information Supplier Page

AZD4017 25mg 25mg  | Purity Not Available

Adooq Bioscience

AZD4017 is a potent, selective, and orally bioavailable11b-HSD1 inhibitor (11b-hydroxysteroid dehydrogenase type 1 inhibitor).

More Information Supplier Page

AZD4017 10mg 10mg  | Purity Not Available

Adooq Bioscience

AZD4017 is a potent, selective, and orally bioavailable11b-HSD1 inhibitor (11b-hydroxysteroid dehydrogenase type 1 inhibitor).

More Information Supplier Page

EC-17 5mg 5mg  | Purity Not Available

Adooq Bioscience

EC-17 is a conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity.

More Information Supplier Page

EC-17 25mg 25mg  | Purity Not Available

Adooq Bioscience

EC-17 is a conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity.

More Information Supplier Page

EC-17 10mg 10mg  | Purity Not Available

Adooq Bioscience

EC-17 is a conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity.

More Information Supplier Page

A-582941 50mg 50mg  | Purity Not Available

Adooq Bioscience

A-582941 is a selective AChR a7 partial agonist. It exhibits high affinity for both rat and human a7 receptors (Ki values are 10.8 and 16.7 nM, respectively).

More Information Supplier Page

Flumatinib mesylate 500mg 500mg  | Purity Not Available

Adooq Bioscience

Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.

More Information Supplier Page